MYDA Advisors’s ArriVent BioPharma AVBP Stock Holding History

MYDA Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-30,000	Closed	-$536K	–	165
2024 Q1	$536K	Buy	+30,000	New	+$605K	0.15%	84

Other funds holding AVBP

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MYDA Advisors's AVBP Position: Q2 2024 in Review

MYDA Advisors sold out of ArriVent BioPharma (AVBP) in Q2 2024, closing a stake of 30,000 shares — an estimated $536K sold.

MYDA Advisors first reported a position in AVBP in Q1 2024 and held it in 1 quarter. The position peaked at $536K in Q1 2024. 54 funds tracked by Wall St. Rank hold AVBP as of Q2 2024.

MYDA Advisors reported no remaining ArriVent BioPharma position as of Q2 2024 after selling out during the quarter.
MYDA Advisors sold 30,000 ArriVent BioPharma shares in Q2 2024, an estimated $536K.
MYDA Advisors first reported a position in ArriVent BioPharma in Q1 2024 and held it in 1 quarter.
MYDA Advisors's ArriVent BioPharma position peaked at $536K in Q1 2024.
54 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2024.

Based on MYDA Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.